Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Article Title: Notoginsenoside R1 treatment facilitated Nrf2 nuclear translocation to suppress ferroptosis via Keap1/Nrf2 signaling pathway to alleviated high-altitude myocardial injury.
doi: 10.1016/j.biopha.2024.116793
Figure Lengend Snippet: Fig. 9. ML385 eliminated the anti-ferroptosis of notoginsenoside R1 in HAMI rats myocardial damage. (A) Western blotting analysis of Keap1, GPX4, SLC7A11, FTH1, HO-1, and TFRC. (B) Effect of ML385 on Nrf2 localization in the nucleus and cytoplasm through Western blotting analysis. (C) Impacts of notoginsenoside R1 on GPX4 and Nrf2 levels was investigated using immunofluorescence staining. Red arrow represents nuclear translocation of Nrf2. Original magnification: ×20. Bar = 50 µm. The values are expressed as the means ± SEM (n = 7). ##P < 0.01, ###P < 0.001, and ####P < 0.0001 versus the HHM group; @@@P < 0.001 and @@@@P < 0.0001 versus the NR1 100 group.
Article Snippet: Dexamethasone (#S1322) and the Nrf2-specific inhibitor ML385 (#S8790) were obtained from Selleck Chemicals (Houston, TX, USA).
Techniques: Western Blot, Immunofluorescence, Staining, Translocation Assay